ANVS News & Events

Annovis Bio announced full enrollment of its pivotal Phase 3 trial evaluating buntanetap in patients with early AD. The trial enrolled 850 patients with pTau217-confirmed AD pathology across 83 clinical sites in the US.

Annovis Bio announced the promotion of Cheng Fang to chief scientific officer. Fang, who joined Annovis in 2021 and most recently served as senior VP, research and development, will lead scientific strategy and research operations across the company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interactions.